Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0
|
作者：
Hernando-Cubero, J. [1 ]
Manzano, J. L. [2 ]
Benavent, M. [3 ]
Lopez, C. [4 ]
Teule, R. [5 ]
Garcia-Carbonero, R. [6 ]
Carmona-Bayonas, A. [7 ]
Crespo, G. [8 ]
Cubillo, A. [9 ]
Jimenez-Fonseca, P. [10 ]
LaCasta, A. [11 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Inst Catala Oncol Badalona, Barcelona, Spain
[3] Hosp Virgen del Rocio, Seville, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Inst Catala Oncol Hosp, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] HJM Morales Meseguer, Murcia, Spain
[8] Hosp Univ Burgos, Burgos, Spain
[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain
[10] Hosp Univ Cent Asturias, Oviedo, Spain
[11] Hosp Univ Donostia, San Sebastian, Spain
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
durvalumab; tremelimumab; neuroendocrine; immunotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J10
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [31] PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)-NCT01280201
    Grande Pulido, Enrique
    Castellano, Daniel E.
    Garcia-Carbonero, Rocio
    Teule, Alex
    Duran, Ignacio
    Fuster, Jose
    Sevilla, Isabel
    Escudero, P.
    Sastre, Javier
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma -: A multiinstitutional Phase II trial
    Ichinose, Y
    Yosimori, K
    Yoneda, S
    Kuba, M
    Kudoh, S
    Niitani, H
    CANCER, 2000, 88 (02) : 318 - 323
  • [33] Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
    von Arx, C.
    Cannella, L.
    Marretta, A. L.
    Bracigliano, A.
    Tatangelo, F.
    Clemente, O.
    Iervolino, D.
    Granata, V.
    Mocerino, C.
    Modica, R.
    Pizzolorusso, A.
    Bianco, A.
    Picozzi, F.
    Di Sarno, A.
    Tafuto, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S708 - S709
  • [34] Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors
    Capdevila, J.
    Bongiovanni, A.
    Hernando, J.
    Spada, F.
    Lopez, C.
    Teule, A.
    Merino, X.
    Lamarca, A.
    Tafuto, S.
    Custodio, A.
    Fazio, N.
    Ibrahim, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 168 - 168
  • [35] NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Elaidi, R. T.
    Pouessel, D.
    Flechon, A.
    Borchiellini, D.
    Barthelemy, P.
    Huillard, O.
    Rouabah, M.
    Braychenko, E.
    Helali, I.
    Audenet, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S723 - S723
  • [36] Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: A Vanderbilt University Cancer Center phase II trial (LUN-46)
    Johnson, DH
    Paul, DM
    Hande, KR
    DeVore, R
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 42 - 46
  • [37] DOLPHIN: Phase II trial of Cisplatin/Etoposide (CTx) plus Radiotherapy (RTx) (RCTx) combined with Durvalumab followed by Durvalumab maintenance versus concomitant RCTx in patients (pts) with limited disease Small Cell Lung Cancer (LD-SCLC)
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Topsch, J.
    Ehrlich, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 254 - 255
  • [38] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
    Kouroussis, C
    Syrigos, K
    Potamianou, A
    Ziras, N
    Ziotopoulos, P
    Stergiou, J
    Ginopoulos, P
    Tselepatiotis, E
    Biozionelou, V
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S
  • [39] Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis
    Zhang, Yaxiong
    Chen, Zihong
    Liu, Yu
    Han, Liang
    Jiang, Wei
    Wang, Qiming
    Shi, Jianhua
    Lu, Liqin
    Li, Jianying
    Zhang, Mingjun
    Huang, Yan
    Yang, Yunpeng
    Hou, Xue
    Zhang, Li
    Li, Jing
    Fang, Wenfeng
    Chen, Gang
    CANCER MEDICINE, 2024, 13 (07):
  • [40] Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instabilityhigh (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
    Raimondi, A.
    Lonardi, S.
    Murgioni, S.
    Cardellino, G.
    Passardi, A.
    Demanzoni, G.
    Strippoli, A.
    Palermo, F.
    Prisciandaro, M.
    Bergamo, F.
    Garattini, S. K.
    Frassineti, G. L.
    Bencivenga, M.
    Randon, G.
    Leone, A. G.
    Nappo, F.
    Mazzaferro, V.
    Sposito, C. F.
    Morano, F.
    Pietrantonio, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S172 - S172
12345